The effects of atorvastatin on antioxidant/antiinflammatory properties of HDLs in hypercholesterolemics

被引:17
作者
Ciftci, Gulsen Akalin [1 ]
Ertorun, Ipek [2 ]
Akalin, Aysen [3 ]
Alatas, Ibrahim Ozkan [2 ]
Musmul, Ahmet [4 ]
机构
[1] Anadolu Univ, Fac Pharm, Dept Biochem, Eskisehir, Turkey
[2] Eskisehir Osmangazi Univ, Fac Med, Dept Med Biochem, Eskisehir, Turkey
[3] Eskisehir Osmangazi Univ, Fac Med, Dept Endocrinol, Eskisehir, Turkey
[4] Eskisehir Osmangazi Univ, Fac Med, Dept Biostat, Eskisehir, Turkey
关键词
Antioxidant/antiinflammatory high-density lipoprotein; atorvastatin; hypercholesterolemia; oxidative stress; ASYMMETRIC DIMETHYLARGININE; REDUCTASE INHIBITORS; OXIDATIVE STRESS; APOLIPOPROTEIN-B; SERUM; PARAOXONASE-1; LIPOPROTEIN(A); CHOLESTEROL; EXPRESSION; THERAPY;
D O I
10.3906/sag-1311-91
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/aim: Hypercholesterolemia is characterized by changes in lipid profile, nitric oxide pathway, and oxidative stress markers, but functions of high-density lipoprotein (HDL) were not well established in hypercholesterolemic subjects treated with atorvastatin. In this study, we aimed to evaluate effects of atorvastatin treatment on functionality of HDL, oxidative stress, and endothelial functions in hypercholesterolemic subjects. Materials and methods: Thirty patients (20 females, 10 males) aged from 40 to 60 years and diagnosed as hypercholesterolemic were included. Patients were treated with 10 mg/day atorvastatin for 3 months. Markers of endothelial functions, namely asymmetric dimethylarginine (ADMA), homocysteine, and nitric oxide (NO), and markers of oxidative status, namely malondialdehyde (MDA), antioxidant potential (AOP), paraoxonase 1 (PON1), and arylesterase, were measured. Before and after atorvastatin treatment, glucose, lipid parameters, and antioxidant/antiinflammatory HDL levels were also measured. Results: ADMA and homocysteine levels were decreased whereas NO levels were increased with atorvastatin therapy. MDA levels were decreased but AOP, PON1, and arylesterase levels and antiinflammatory characteristics of HDLs were increased. Furthermore, lipid profiles of the patients improved with atorvastatin therapy. Conclusion: Hypercholesterolemia is a cause of oxidative stress, endothelial dysfunction, and proinflammatory HDL levels. Atorvastatin is a beneficial pharmacological modulator of impaired antiinflammatory HDL-C levels, endothelial functions, and oxidative status against atherosclerosis indicating pleiotropic effects of statins.
引用
收藏
页码:345 / 351
页数:7
相关论文
共 36 条
[1]   The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment [J].
Andrikoula, M. ;
McDowell, I. F. W. .
DIABETES OBESITY & METABOLISM, 2008, 10 (04) :271-278
[2]   Anti-inflammatory properties of HDL [J].
Ansell, BJ ;
Navab, M ;
Watson, KE ;
Fonarow, GC ;
Fogelman, AM .
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2004, 5 (04) :351-358
[3]   Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5 hydroxymethylglutaryl coenzyme a reductase inhibitors on non-high-density lipoprotein cholesterol levels [J].
Ballantyne, CM ;
Andrews, TC ;
Hsia, JA ;
Kramer, JH ;
Shear, C .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (03) :265-269
[4]  
Beltowski J, 2002, POL J PHARMACOL, V54, P661
[5]  
Beltowski J, 2002, POL J PHARMACOL, V54, P143
[6]  
Beltowski J, 2006, PHARMACOL REP, V58, P159
[7]   The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor [J].
Böger, RH .
CARDIOVASCULAR RESEARCH, 2003, 59 (04) :824-833
[8]   Effects of atorvastatin therapy on hypercholesterolernic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine [J].
Bolayirli, Ibrahim Murat ;
Aslan, Mahmure ;
Balci, Huriye ;
Altug, Tuncay ;
Hacibekiroglu, Munire ;
Seven, Arzu .
LIFE SCIENCES, 2007, 81 (02) :121-127
[9]   The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: Relation to low-density lipoprotein receptor gene polymorphism [J].
Bolewski, Andrzej ;
Lipiecki, Janusz ;
Plewa, Robert ;
Burchardt, Pawel ;
Siminiak, Tomasz .
CARDIOLOGY, 2008, 111 (02) :140-146
[10]  
BRANCHI A, 1995, INT J CLIN PHARM TH, V33, P345